治疗前HIV耐药对死亡率、脱失和病毒抑制的影响及传播网络:中国西南观察性队列研究
该研究在中国西南开展2014–2022年观察性队列,纳入3478例启动抗逆转录病毒治疗(ART)的患者,分析治疗前耐药(PDR)对死亡率、脱失和病毒抑制的影响。PDR总患病率为6.4%,PDR与脱失风险增加和病毒抑制率降低显著相关,尤其对依非韦伦/奈韦拉平耐药者,但与死亡率无显著关联。
要点
- PDR总患病率6.4%,NNRTI耐药率4.1%最常见。
- PDR与脱失风险增加相关,总体调整HR 1.67(95%CI 1.11–2.52)。
- PDR组病毒抑制显著降低,AOR 0.46(95%CI 0.27–0.77)。
核心结论
- 中国西南地区PDR患病率中等,与脱失和病毒学失败风险增加显著相关。
- 依非韦伦/奈韦拉平耐药者脱失和病毒抑制不良风险尤为突出。
- 研究支持在启动ART前常规进行PDR检测以指导优化一线治疗方案。
研究设计与样本
- 2014–2022年在中国西南开展观察性队列研究。
- 共纳入3478例符合条件、启动ART的患者。
- 使用Stanford HIV Drug Resistance Database分析PDR,用HIV-TRACE构建分子传播网络。
- 采用Cox和logistic回归评估PDR对结局的影响。
主要发现
- 总体PDR患病率为6.4%;NNRTI、NRTI和PI耐药率分别为4.1%、1.3%和1.1%。
- 总体死亡率为4.58/100人年,脱失率为2.40/100人年。
- PDR与死亡率无显著关联,但与脱失风险增加相关:总体耐药组调整HR 1.67(95%CI 1.11–2.52),NNRTI耐药组2.16(95%CI 1.36–3.43),依非韦伦/奈韦拉平耐药组2.09(95%CI 1.10–3.97)。
- 病毒抑制在耐药组显著降低:总体耐药组AOR 0.46(95%CI 0.27–0.77),NNRTI耐药组AOR 0.42(95%CI 0.22–0.78),依非韦伦/奈韦拉平耐药组AOR 0.41(95%CI 0.21–0.81)。
临床怎么用
- 对启动ART的患者,尤其存在NNRTI或依非韦伦/奈韦拉平耐药风险者,应考虑治疗前PDR检测。
- 根据PDR结果选择优化的一线ART方案,以降低脱失和病毒学失败风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Pretreatment drug resistance (PDR) compromises antiretroviral therapy (ART) efficacy and is a major concern in HIV care, yet its consequences for key treatment outcomes are not well-defined. We therefore systematically investigated the prevalence of PDR and its impact on mortality, attrition and viral suppression amongst patients starting ART. METHODS: An observational cohort study was conducted in Southwest China, 2014-2022. PDR was analysed using the Stanford HIV Drug Resistance Database. Molecular transmission networks were constructed with HIV-TRACE. Cox and logistic regression evaluated the impact of PDR. RESULTS: Amongst 3478 eligible patients, the overall prevalence of PDR was 6.4%. PDR rates to non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors and protease inhibitors were 4.1%, 1.3% and 1.1%, respectively. The overall mortality and attrition rates were 4.58 and 2.40 per 100 person-years, respectively. Whilst PDR showed no significant association with mortality, it was associated with increased attrition. Compared to those without resistance, the adjusted HR (95% CI) for attrition was 1.67 (1.11-2.52) in the overall drug-resistant group, 2.16 (1.36-3.43) in the NNRTI-resistant group and 2.09 (1.10-3.97) in the efavirenz/nevirapine-resistant group. Viral suppression was significantly lower in the drug-resistant group [adjusted odds ratio (AOR): 0.46; 95% CI: 0.27-0.77], the NNRTI-resistant group (AOR: 0.42; 95% CI: 0.22-0.78) and the efavirenz/nevirapine-resistant group (AOR: 0.41; 95% CI: 0.21-0.81). CONCLUSIONS: Our study reveals a moderate prevalence of PDR in Southwest China, significantly associated with increased risk of attrition and virologic failure, particularly amongst patients with resistance to efavirenz/nevirapine. Our findings strongly advocate for routine PDR testing prior to ART initiation to guide optimal first-line treatment strategies.
引用
- Qin L, Xie Y, Li J, et al. Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China. J Antimicrob Chemother. 2026. PMID: 41770585. doi:10.1093/jac/dkag073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。